Taking on lousy side effects of existing meds, NEA-backed Xoc tackles Parkinson’s/migraines with $30M Series A
New Enterprise Associates is backing a startup near San Jose that’s using old clinical data — paired with new tech — to come up with novel drugs for Parkinson’s disease and migraines. By mimicking the things that work in old drugs while abandoning side-effect-causing triggers, the hope is to design drugs that lack the grim reactions of those already on the market.
The company, called Xoc (pronounced “shock”) Pharmaceuticals, raised $30 million in this new Series A round led by NEA (one of the world’s largest venture firms, with $18 billion in assets under management).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.